dexelvucitabine dexelvucitabine dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. it is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits hiv-1 replication in vitro. during phase ii clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus. dexelvucitabine names iupac name 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine systematic iupac name 4-amino-5-fluoro-1-pyrimidin-2(1h)-one other names reverset identifiers cas number 134379-77-4 y 3d model (jsmol) interactive image chembl chembl109831 n chemspider 58498 n kegg d03981 y pubchem cid 64973 unii ku8spj271w y comptox dashboard (epa) dtxsid20158678 inchi inchi=1s/c9h10fn3o3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14h,4h2,(h2,11,12,15)/t5-,7+/m0/s1 nkey: hsbkfspndwwpsl-cahluqpwsa-n ninchi=1/c9h10fn3o3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14h,4h2,(h2,11,12,15)/t5-,7+/m0/s1key: hsbkfspndwwpsl-cahluqpwbd smiles f\c1=c\n(c(=o)\n=c1\n)/2o(\c=c\2)co properties chemical formula c9h10fn3o3 molar mass 227.195 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references on april 3, 2006, pharmasset and incyte, the pharmaceutical companies developing dexelvucitabine, announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme lipase in the bloodstream) in a phase ii trial.